The effect of estroprogestagen therapy on lipid status in menopause depending on the drug administration route

Goran Čitlučanin; Miomira Ivović; Milina Tančić-Gajić; Fadil Canović; Miloš Stojanović; Ljiljana Marina; Zorana Arizanović; Aleksandar Djogo; Svetlana Vujović; Vladimir  Gerginić

doi:10.2298/VSP170318080C

Goran Čitlučanin Outpatient Department “Voždovac”, Belgrade
Miomira Ivović Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Milina Tančić-Gajić Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Fadil Canović Outpatient Department “Zemun”, Belgrade
Miloš Stojanović Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Ljiljana Marina Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Zorana Arizanović Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Aleksandar Djogo Clinical Center Podgorica, Podgorica
Svetlana Vujović University of Belgrade, Faculty of Medicine, Belgrade
Vladimir Gerginić ; University of Belgrade, Faculty of Medicine, Belgrade

DOI: https://doi.org/10.2298/VSP170318080C

Keywords: hormone replacement therapy;, cardiovascular diseases;, lipids;, menopause

Abstract

Background/Aim. In menopausal women lipid and lipoprotein values are important predictors of development of cardiovascular diseases (CVD). The use of estrogens reduces levels of low density lipoprotein cholesterol (LDL-C) and lipoprotein A [Lp(a)], and increases levels of triglycerides (TG) and high density lipoprotein cholesterol (HDL-C) depending on the dose and route of administration. Simultaneous administration of progesterone, depending on the type, can have different effects on lipids. The aim of the study was to examine the effect of estroprogestagen therapy on the lipid metabolism of women in menopause, depending on the administration route. Methods. A study was conducted as prospective clinical interventional study with controlled parallel groups. It included 64 women in menopause, divided into three groups: the group 1 (n = 22) on oral therapy with estroprogestagens, the group 2 (n = 17) on transdermal patch therapy with estroprogestagens and the group 3 (n = 25) treated with estroprogestagens given intramuscularly. The following biochemical parameters in the serum were determined: total cholesterol (TC), HDL-C, LDL-C, TG, Lp(a), apoprotein A (Apo-A), apoprotein B (Apo-B), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, progesterone, testosterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-SO₄), prolactin and thyroid-stimulating hormone (TSH), prior to administration of the menopausal hormonal therapy (MHT), as well as after sixth months and 2–5 years from the beginning of the therapy. The statistical significance of the difference in values obtained was examined independently and depending on the route of MHT application. Results. MHT, regardless of the administration route, led to a statistically significant continuous decrease of TC, LDL-C and Apo-B levels and the continuous increase of HDL-C and Apo-A levels. Serum levels of TC, LDL-C, HDL-C, Lp(a), Apo-A and Apo-B did not show a statistically significant differences among groups of women given MHT by different routes. It was found that the serum level of Apo-A increased significantly with the rise of estradiol, and the values of LDL and Apo-B decreased regardless of the route of the MHT application. Conclusion. MHT introduced in time, regardless of the route of administration, has beneficial effects on the lipid status of menopausal women and consequently might prevent numerous cardiovascular diseases that are the leading cause of mortality.

Author Biographies

Goran Čitlučanin, Outpatient Department “Voždovac”, Belgrade

Primaruis, magistar medicinskih nauka, specijalista opste medicine

Fadil Canović, Outpatient Department “Zemun”, Belgrade

specijalista ginekologije i akuserstva

Svetlana Vujović, University of Belgrade, Faculty of Medicine, Belgrade

Doktor medicinskih nauka, Specijalista interne medicine i endokrinologije, Redovi profesor Medicinskog fakulteta Univerziteta u Beogradu,

References

Jouyandeh Z, Nayebzadeh F, Qorbani M, Asadi M. Metabolic syndrome and menopause. J Diabetes Metab Disord 2013; 12(1): 1.

Gravena AA, Brischiliari SC, Lopes TC, Agnolo CM, Carvalho MD, Pelloso SM. Excess weight and abdominal obesity in postmenopausal Brazilian women: a population-based study. BMC Womens Health 2013; 13: 46.

Arthur FK, Adu-Frimpong M, Osei-Yeboah J, Mensah FO, Owusu L. The prevalence of metabolic syndrome and its predominant components among pre-and postmenopausal Ghanaian women. BMC Res Notes 2013; 6: 446.

Vujović S. Menopause. Belgrade: Kosmos; 1998. (Serbian)

Dopsaj V, Šumarac Z. Changes in biochemical parameters in menopause. Arh Farm 2005; 55(2): 76–90. (Serbian)

Gotto AM. Fundamentals of blood lipid metabolism and concepts in atherogenesis. In: Gotto AM, editor. Contemporary Diagnosis and Management of Lipid Disorders. 2nd ed. Pennsylvania, USA: Handbooks in Health Care Co; 2001, p. 27–55.

Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88(6): 2404–11.

Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012; 345: e6409.

Baber RJ, Panay N, Fenton A. IMS Writing Group.2016 IMS Recommendations on women’s midlife health and menopause hormone therapy, Climacteric 2016; 19(2): 109–50.

Jensen J, Nilas L, Christiansen C. Influence of the Menopause on Serum Lipids and Lipoproteins. Maturitas 1990; 12(4): 321–5.

Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; (3): CD002229.

The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7): 728–53.

Feingold K, Brinton EA, Grunfeld C. The Effect of Endocrine Disorders on Lipids and Lipoproteins. 2017 Feb 24. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, et al, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: http://www.ncbi.nlm.nih.gov/books/NBK409608/ [Updated 2017 Feb 24].

Coelingh Bennink HJ. Are all estrogens the same? Maturitas 2004; 47(4): 269–75.

Comitato R, Saba A, Turrini A, Arganini C, Virgili F. Sex hormons and macronutritient metabolism. Crit Rev Food Sci Nutr 2015; 55(2): 227–41.

McCarthy JJ. Gene by sex interaction in the etiology of coronary heart disease and the preceding metabolic syndrome. Nutr Metab Cardiovasc Dis 2006; 17(2): 153–61.

Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Guthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 2000; 101(22): 2572–8.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133(12): 933–41.

Omodei U, Boccuti AM, Ruggeri C, Fallo, L. A New HRT Regimen Using Estradiol Valerate and Cyproterone Acetate: Clinical Data. Menopause 1995; 2(4): 270–4.

Mattsson LA, Samsioe G, von Schoultz B, Uvebrant M, Wiklund I. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. Br J Obstet Gynaecol 1993; 100(5): 450–3.

Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75(5): 898–915.

Krauss MR. Lipids and Lipoproteins and Effects of Hormone Replacement. Chapter 32. In: Lobo RA, editor. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects 2 nd ed. Philadelphia: Lippincott Williams&Wilkins; 1999. p. 461.

Jensen J, Nilas L, Christiansen C. Influence of the Menopause on Serum Lipids and Lipoproteins. Maturitas 1990; 12(4): 321–5.

Soma MR, Meschia M, Bruschi F, Morrisett JD, Paoletti R, Fumagalli R, et al. Hormonal agents used in lowering lipoprotein(a). Chem Phys Lipids 1994; 67–68: 345–50.

Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Chełstowski K, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005; 54(1): 72–8.

Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325(17): 1196–204.

Fait T, Vrablík M, Zizka Z, Trnková B, Masata J, Zivný J. Effect of early onset of transdermal and oral estrogen therapy on the lipid profile: a prospective study with cross-over design. Ceska Gynekol 2006; 71(3): 226–30. (Czech)

Camilli A, Di Benedetto L, Camilli FM, Ermini M. The effects of hormone replacement therapy (HRT) on lipid metabolism in the menopause. Minerva Ginecol 1997; 49(5): 199–202. (Italian)

Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. Aust N Z J Obstet Gynaecol. 2003; 43(3): 213–6.

Duncan GW, Kirton KT. Depo-Provera: Pharmacology and toxicology. In: Zambrano D, editor. Depo-provera (medro-xyprogesterone acetate) for contraception: A current per-spective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. Oxford, England: Oxford Clinical Communications; 1992. p. 7– 25.

Hirvonen E, Malkonen M, Manninen V. Effects of Different Progestin on Lipoprotein During Postmenopausal Repla¬ce-ment Therapy. N Engl J Med 1981; 304(10): 500–3.

Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas 2017; 99: 27–36.

Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause 1998; 5(3): 157–62.

Beck KL, Anderson MC, Kirk JK. Transdermal estrogens in the changing landscape of hormone replacement therapy. Postgrad Med 2017; 129(6): 632–6.